Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Cyclin D-CDK4 relieves cooperative repression of proliferation and cell cycle gene expression by DREAM and RB.

Schade AE, Oser MG, Nicholson HE, DeCaprio JA.

Oncogene. 2019 Mar 4. doi: 10.1038/s41388-019-0767-9. [Epub ahead of print]

PMID:
30833638
2.

Differential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.

Nasir A, Holzer TR, Chen M, Man MZ, Schade AE.

Cancer Cell Int. 2017 May 19;17:56. doi: 10.1186/s12935-017-0427-5. eCollection 2017.

3.

Variability in Platelet-Derived Growth Factor Receptor Alpha Antibody Specificity May Impact Clinical Utility of Immunohistochemistry Assays.

Holzer TR, O'Neill Reising L, Credille KM, Schade AE, Oakley GJ.

J Histochem Cytochem. 2016 Dec;64(12):785-810.

4.

Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.

Holzer TR, Fulford AD, Reising LO, Nedderman DM, Zhang X, Benjamin LE, Schade AE, Nasir A.

Anticancer Res. 2016 Jul;36(7):3277-88.

PMID:
27354584
5.

Heterogeneity of Vascular Endothelial Growth Factor Receptors 1, 2, 3 in Primary Human Colorectal Carcinoma.

Nasir A, Reising LO, Nedderman DM, Fulford AD, Uhlik MT, Benjamin LE, Schade AE, Holzer TR.

Anticancer Res. 2016 Jun;36(6):2683-96.

PMID:
27272777
6.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.

Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, Martinez R, Kulanthaivel P, Li LQ, Frenzel M, Cronier DM, Chan EM, Flaherty KT, Wen PY, Shapiro GI.

Cancer Discov. 2016 Jul;6(7):740-53. doi: 10.1158/2159-8290.CD-16-0095. Epub 2016 May 23.

7.

Advanced Companion Diagnostics Facilities: Opportunity Favors the Prepared Laboratory.

Gruver AM, Schade AE.

Arch Pathol Lab Med. 2015 Oct;139(10):1201. doi: 10.5858/arpa.2015-0095-LE. No abstract available.

PMID:
26414461
8.

Immunohistochemical application of a highly sensitive and specific murine monoclonal antibody recognising the extracellular domain of the human hepatocyte growth factor receptor (MET).

Gruver AM, Liu L, Vaillancourt P, Yan SC, Cook JD, Roseberry Baker JA, Felke EM, Lacy ME, Marchal CC, Szpurka H, Holzer TR, Rhoads EK, Zeng W, Wortinger MA, Lu J, Chow CK, Denning IJ, Beuerlein G, Davies J, Hanson JC, Credille KM, Wijayawardana SR, Schade AE.

Histopathology. 2014 Dec;65(6):879-96. doi: 10.1111/his.12510. Epub 2014 Oct 6.

9.

Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lung.

Holzer TR, Fulford AD, Nedderman DM, Umberger TS, Hozak RR, Joshi A, Melemed SA, Benjamin LE, Plowman GD, Schade AE, Ackermann BL, Konrad RJ, Nasir A.

PLoS One. 2013 Nov 14;8(11):e80292. doi: 10.1371/journal.pone.0080292. eCollection 2013.

10.

Considerations in the development of circulating tumor cell technology for clinical use.

Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, Hayes DF, Kapke G, Kumar P, Lee JSh, Liu MC, McCormack R, Mikulski S, Nagahara L, Pantel K, Pearson-White S, Punnoose EA, Roadcap LT, Schade AE, Scher HI, Sigman CC, Kelloff GJ.

J Transl Med. 2012 Jul 2;10:138. doi: 10.1186/1479-5876-10-138. Review.

11.

Circulating human hepcidin-25 concentrations display a diurnal rhythm, increase with prolonged fasting, and are reduced by growth hormone administration.

Troutt JS, Rudling M, Persson L, Ståhle L, Angelin B, Butterfield AM, Schade AE, Cao G, Konrad RJ.

Clin Chem. 2012 Aug;58(8):1225-32. doi: 10.1373/clinchem.2012.186866. Epub 2012 Jun 7.

12.

Ischemic time impacts biological integrity of phospho-proteins in PI3K/Akt, Erk/MAPK, and p38 MAPK signaling networks.

Holzer TR, Fulford AD, Arkins AM, Grondin JM, Mundy CW, Nasir A, Schade AE.

Anticancer Res. 2011 Jun;31(6):2073-81.

PMID:
21737625
13.

Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria.

Jankowska AM, Szpurka H, Calabro M, Mohan S, Schade AE, Clemente M, Silverstein RL, Maciejewski JP.

Haematologica. 2011 Jul;96(7):954-62. doi: 10.3324/haematol.2010.029298. Epub 2011 May 5.

14.

Check Sample Abstracts.

Alter D, Grenache DG, Bosler DS, Karcher RE, Nichols J, Rajadhyaksha A, Camelo-Piragua S, Rauch C, Huddleston BJ, Frank EL, Sluss PM, Lewandrowski K, Eichhorn JH, Hall JE, Rahman SS, McPherson RA, Kiechle FL, Hammett-Stabler C, Pierce KA, Kloehn EA, Thomas PA, Walts AE, Madan R, Schlesinger K, Nawgiri R, Bhutani M, Kanber Y, Abati A, Atkins KA, Farrar R, Gopez EV, Jhala D, Griffin S, Jhala K, Jhala N, Bentz JS, Emerson L, Chadwick BE, Barroeta JE, Baloch ZW, Collins BT, Middleton OL, Davis GG, Haden-Pinneri K, Chu AY, Keylock JB, Ramoso R, Thoene CA, Stewart D, Pierce A, Barry M, Aljinovic N, Gardner DL, Barry M, Shields LB, Arnold J, Stewart D, Martin EL, Rakow RJ, Paddock C, Zaki SR, Prahlow JA, Stewart D, Shields LB, Rolf CM, Falzon AL, Hudacki R, Mazzella FM, Bethel M, Zarrin-Khameh N, Gresik MV, Gill R, Karlon W, Etzell J, Deftos M, Karlon WJ, Etzell JE, Wang E, Lu CM, Manion E, Rosenthal N, Wang E, Lu CM, Tang P, Petric M, Schade AE, Hall GS, Oethinger M, Hall G, Picton AR, Hoang L, Imperial MR, Kibsey P, Waites K, Duffy L, Hall GS, Salangsang JA, Bravo LT, Oethinger MD, Veras E, Silva E, Vicens J, Silva E, Keylock J, Hempel J, Rushing E, Posligua LE, Deavers MT, Nash JW, Basturk O, Perle MA, Greco A, Lee P, Maru D, Weydert JA, Stevens TM, Brownlee NA, Kemper AE, Williams HJ, Oliverio BJ, Al-Agha OM, Eskue KL, Newlands SD, Eltorky MA, Puri PK, Royer MC, Rush WL, Tavora F, Galvin JR, Franks TJ, Carter JE, Kahn AG, Lozada Muñoz LR, Houghton D, Land KJ, Nester T, Gildea J, Lefkowitz J, Lacount RA, Thompson HW, Refaai MA, Quillen K, Lopez AO, Goldfinger D, Muram T, Thompson H.

Am J Clin Pathol. 2009 Feb;131(2):286-299.

PMID:
19176368
15.

Altered lipid raft composition and defective cell death signal transduction in glycosylphosphatidylinositol anchor-deficient PIG-A mutant cells.

Szpurka H, Schade AE, Jankowska AM, Maciejewski JP.

Br J Haematol. 2008 Jul;142(3):413-22. doi: 10.1111/j.1365-2141.2008.07203.x. Epub 2008 Jun 9.

PMID:
18544084
16.

Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F.

Gibson SE, Schade AE, Szpurka H, Bak B, Maciejewski JP, Hsi ED.

Hum Pathol. 2008 Jul;39(7):1111-4. doi: 10.1016/j.humpath.2007.10.034. Epub 2008 May 13.

PMID:
18479730
17.

Immunomodulation via targeted inhibition of antigen receptor signal transduction.

Schade AE, Gonzalez-Stawinski G.

Cardiovasc Hematol Disord Drug Targets. 2008 Mar;8(1):1-6. Review.

PMID:
18336251
18.

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation.

Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, Szpurka H, Maciejewski JP.

Blood. 2008 Feb 1;111(3):1366-77. Epub 2007 Oct 25.

19.

The role of HLA-G in gastrointestinal inflammatory disease and malignancy.

Downs-Kelly E, Schade AE, Hansel DE.

Semin Cancer Biol. 2007 Dec;17(6):451-8. Epub 2007 Jul 13. Review.

PMID:
17716911
20.

T-large granular lymphocyte leukemia: current molecular concepts.

Wlodarski MW, Schade AE, Maciejewski JP.

Hematology. 2006 Aug;11(4):245-56. Review.

PMID:
17178663
21.

Pathophysiology defined by altered signal transduction pathways: the role of JAK-STAT and PI3K signaling in leukemic large granular lymphocytes.

Schade AE, Wlodarski MW, Maciejewski JP.

Cell Cycle. 2006 Nov;5(22):2571-4. Epub 2006 Nov 15. Review.

PMID:
17172839
22.

Phosphatidylinositol-3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis.

Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP.

Blood. 2006 Jun 15;107(12):4834-40. Epub 2006 Feb 16.

23.
24.
25.

Signal transduction through the T cell receptor is dynamically regulated by balancing kinase and phosphatase activities.

Schade AE, Levine AD.

Biochem Biophys Res Commun. 2002 Aug 23;296(3):637-43.

PMID:
12176029

Supplemental Content

Loading ...
Support Center